TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06573476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRC supported text + AI driven CSDH-enhanced text
Description: In interventional Arm-1, PRC-supported text check-ins to participants (3x/week) will be provided by PRC study staff in addition to automated AI-driven texts. The PRC will personalize text check-ins to participants based on: (a) baseline CSDH needs (e.g., food insecurity, legal aid); (b) initial intake visit in primary care or challenges with service entry; and (c) content outlined in the CSH training addressing emerging participant challenges.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI driven CSDH-enhanced text only
Description: In interventional Arm-2, participants will receive the AI-driven CSDH-enhanced text messaging only. Participants in this arm will not receive text support from the PRC.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: In Arm-3, the control group, individuals randomized to the control arm will receive treatment as usual (i.e., verbal instructions and NYC Dept of Health pamphlets detailing access to OUD and social services). No services will be provided except for social/clinical service referrals given at the end of each REDCap visit.
Study: NCT06573866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory workplace intervention
Description: The Participatory Workplace Intervention (PWI) is a process intervention in which a trained process facilitator guides an employee and their manager in identifying work-related obstacles and finding solutions to overcome or manage these obstacles. Its primary goal is to achieve consensus between employee and manager with respect to the most obstructive obstacles for functioning at work and feasible solutions. Following consensus, the stakeholders formulate and agree upon a plan of action and execute the plan. Subsequently, the implementation (process) of the plan of action will be evaluated. Six months after the evaluation, a follow-up will take place to determine whether new obstacles have emerged and whether a new cycle of process steps should be initiated.
Study: NCT06309199

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biogaia
Description: Biogaia is a probiotics product that contain Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil
Study: NCT06572800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiviTum-TKa
Description: Analyze blood samples by DiviTum-TKa
Study: NCT06573593

Intervention type: DRUG
Intervention: Tofacitinib
Description: In the real-world settings, patients with AA treated with tofacitinib.

Intervention type: DRUG
Intervention: Baricitinib
Description: In the real-world settings, patients with AA treated with Baricitinib.

Intervention type: DRUG
Intervention: Ruxolitinib
Description: In the real-world settings, patients with AA treated with Ruxolitinib.

Intervention type: DRUG
Intervention: Upadacitinib
Description: In the real-world settings, patients with AA treated with Upadacitinib.

Intervention type: DRUG
Intervention: Abrocitinib
Description: In the real-world settings, patients with AA treated with Abrocitinib.

Intervention type: DRUG
Intervention: Ritlecitinib
Description: In the real-world settings, patients with AA treated with Ritlecitinib.
Study: NCT05635747

Intervention type: DEVICE
Intervention: Relizorb Enzyme Cartridge
Description: Tube feeds run across device to digest fats.
Study: NCT06024954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy
Description: Patients in the aromatherapy group use 5% lavender oil with a diffuser for 15-20 minutes in accordance with the Aromatherapy-Clinical Guideline For Midwives. NHS.~Trust 1-15) has been applied. The diffuser was placed 30 cm from the participants and five (5) drops of essential lavender oil were placed on the filter paper. Within 10-15 minutes after the completion of the inhalation, data collection forms were applied again, and pain, anxiety, blood pressure, pulse and respiratory rate were evaluated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Description: The relaxing music group listened to specially composed MusiCure® compositions in soft rhythm, including melodies with harp, cello, strings and sound elements from nature (eg rain, bird, forest sound). Listened with headphones for 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy and music therapy
Description: Inpatients will be given music with a loudspeaker with the effect of aromatherapy inhaler for three consecutive days. Within 10-15 minutes after the completion of the inhalation, data collection forms will be applied again, pain, anxiety, blood pressure, pulse, respiratory rate were evaluated.
Study: NCT04751916

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential Amino Acid Protein Supplement
Description: Proprietary essential amino acid protein supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beneprotein®
Description: Whey protein supplement
Study: NCT05591677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine
Description: D-cycloserine (DCS) is a partial NMDA receptor agonist that has demonstrable impact on rTMS and TBS's neuromodulatory effects. Participants will be asked to orally ingest one capsule 2-hours prior to their scheduled iTBS treatment time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine
Description: D-cycloserine (DCS) is a partial NMDA receptor agonist that has demonstrable impact on rTMS and TBS's neuromodulatory effects. Participants will be asked to orally ingest one capsule 2-hours prior to their scheduled iTBS treatment time.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation
Description: Intermittent Theta Burst Stimulation (iTBS) will be administered with a magnetic stimulator using a figure-of-8 coil or equivalent FDA-approved device. Initial treatment coil localisation and individual calibration of stimulation intensity will be conducted by TMS-trained investigators/staff using standard approaches.67,68 Stimulation intensity will be at 90% of the individual's calibrated resting motor threshold. iTBS treatment session delivers 600 pulses and is approximately 3½ minutes in duration. The total pulse number applied over a course of 20 treatments will be 12,000. This regimen is analogous with the iTBS protocol approved by the US FDA to treat TRD.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation
Description: Intermittent Theta Burst Stimulation (iTBS) will be administered with a magnetic stimulator using a figure-of-8 coil or equivalent FDA-approved device. Initial treatment coil localisation and individual calibration of stimulation intensity will be conducted by TMS-trained investigators/staff using standard approaches.67,68 Stimulation intensity will be at 90% of the individual's calibrated resting motor threshold. iTBS treatment session delivers 600 pulses and is approximately 3½ minutes in duration. The total pulse number applied over a course of 20 treatments will be 12,000. This regimen is analogous with the iTBS protocol approved by the US FDA to treat TRD.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation
Description: Intermittent Theta Burst Stimulation (iTBS) will be administered with a magnetic stimulator using a figure-of-8 coil or equivalent FDA-approved device. Initial treatment coil localisation and individual calibration of stimulation intensity will be conducted by TMS-trained investigators/staff using standard approaches.67,68 Stimulation intensity will be at 90% of the individual's calibrated resting motor threshold. iTBS treatment session delivers 600 pulses and is approximately 3½ minutes in duration. The total pulse number applied over a course of 20 treatments will be 12,000. This regimen is analogous with the iTBS protocol approved by the US FDA to treat TRD.
Study: NCT04902105

Intervention type: DRUG
Group type: OTHER
Intervention: ecopipam HCL
Description: oral tablets

Intervention type: DRUG
Group type: OTHER
Intervention: ecopipam HCL
Description: oral tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Mefenamic acid
Description: oral capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Divalproex Sodium ER
Description: oral tablets
Study: NCT06701903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-1284 10 mg
Description: ITI-1284 10 mg tablet, taken once daily, sublingual administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-1284 20 mg
Description: ITI-1284 20 mg tablet, taken once daily, sublingual administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet, taken once daily, sublingual administration
Study: NCT04833257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP combine with Tislelizumab neoadjuvant therapy+CCRT
Description: chemotherapy combine with anti-PD-1 targeted immunotherapy+concurrent chemotherapy
Study: NCT05278156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL500036 - low dose
Description: CPL500036 is to be oral administered. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL500036 - high dose
Description: CPL500036 is to be oral administered. Each patient is to take 4 capsules with active substance daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is to be oral administered. Each patient is to take 4 capsules of placebo daily.
Study: NCT04874922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gestational Diabetes Training Intervention based on Planned Behavior Theory
Description: On the basis of Planned Behavior Theory, an training intervention is planned in three stages for medical nutrition, physical activity and gestational diabetes follow-up.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Gestational Diabetes Training Intervention based on standart
Description: Standard training for gestational diabetes will be given once at 28 weeks of gestation.
Study: NCT05723523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CI-CDS
Description: The CI-CDS system is a clinical decision support tool that assists clinicians in the diagnosis and management of cognitive impairment.
Study: NCT06234371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: The intervention is offering a $500 gift card as an incentive for completing 6 counseling sessions to eligible individuals randomized into the treatment group. Another $500 gift card will be given after completing 12 counseling sessions, and another $500 gift card will be given after completing 18 counseling sessions.
Study: NCT06702098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iNK cells
Description: Induced pluripotent stem cells derived NK cells.
Study: NCT06700850

Intervention type: DEVICE
Group type: OTHER
Intervention: Prototype dressing rectangle
Description: Prototype multilayer foam wound dressing with polyurethane, cellulose, superabsorbent polymer, silicone adhesive, acrylic adhesive. LDPE (Low Density Polyethylene). Size: 30x10cm. Topical application. Single use.

Intervention type: DEVICE
Group type: OTHER
Intervention: Marketed dressing rectangle
Description: CE marked multilayer foam wound dressing with silicone, polyurethane, viscose, polyester, polyolefins, polyacrylate and superabsorbent acrylate fibres. Size: 30x10cm. Topical application. Single use

Intervention type: DEVICE
Group type: OTHER
Intervention: Prototype dressing square
Description: Prototype multilayer foam wound dressing with polyurethane, cellulose, superabsorbent polymer, silicone adhesive, acrylic adhesive. LDPE (Low Density Polyethylene). Size: 7.5x7.5cm. Topical application. Single use.

Intervention type: DEVICE
Group type: OTHER
Intervention: Marketed dressing square
Description: CE marked multilayer foam wound dressing with silicone, polyurethane, viscose, polyester, polyolefins, polyacrylate and superabsorbent acrylate fibres. Size: 7.5x7.5cm. Topical application. Single use.
Study: NCT06704022

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement
Description: Consumption of the oral nutritional supplement
Study: NCT06703047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA+pd-1+chemo
Description: All trans tretinoic acid+tislelizumab+chemotherapy (paclitaxel, cisplatin, or carboplatin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo+PD-1+chemo
Description: Placebo+tislelizumab+chemotherapy (paclitaxel, cisplatin, or carboplatin)
Study: NCT05793060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride
Description: Dexmedetomidine 50 Mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Phosphate
Description: Dexamethasone 4 mg
Study: NCT04579367

Intervention type: DRUG
Intervention: Bempedoic acid and/or its fixed-dose combination with ezetimibe
Description: This is a non-interventional study. No study medication will be provided to the patients. Medication will be prescribed by the treating physician in line with the clinical practice.
Study: NCT05456321

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: Active Transcranial Direct Current Stimulation (tDCS)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Computerized Cognitive Training

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Training
Description: Computerized Cognitive Training

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham Transcranial Direct Current Stimulation (tDCS)
Study: NCT04479943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MOVIN
Description: MOVIN is a multi-component unit-based intervention comprised of five components that are implemented simultaneously in a hospital unit. The five components are: 1) psychomotor skills training, 2) unit ambulation culture, 3) communication, 4) resources, 5) ambulation environment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys and Focus groups
Description: Nurses will answer surveys about nurse behavior, changes in self-efficacy, frequency and distance of patient ambulation, documentation of ambulation, qualitative data collected to determine barriers to implementation
Study: NCT06023680

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous sedentary reduction intervention
Description: During Phase 1, one minute of sedentary time will be replaced with very light to light intensity walking at three different times during the day, every day for 10 days, reaching three separate 10-minute walking intervals (or bouts).~During Phase 2, the three 10-minute walking bouts will be gradually combined into one 30-minute bout over the course of 20 days.
Study: NCT05621239

Intervention type: BIOLOGICAL
Intervention: BNT162b2
Description: BNT162b2 half dose and full dose
Study: NCT06023680

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bouted sedentary reduction intervention
Description: During Phase 1, one minute of sedentary time will be replaced with very light to light intensity walking at three different times during the day, every day for 10 days, reaching three separate 10-minute walking intervals (or bouts).~During Phase 2, the three 10-minute walking bouts will be maintained over the course of 20 days.
Study: NCT05297734

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Receive technology-based supportive cancer care
Description: All participants will receive an electronic health record message or email with standardized information provided regarding advance care planning and symptom management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receive redesigned team-based supportive cancer care
Description: Lay Health Workers will meet with 1:1 with participants over 12 months to discuss advance care planning, surrogate decision-makers, advance directives and physician orders for life sustaining treatment.
Study: NCT06452316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSB-001 Ophthalmic Solution 0.1%
Description: CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSB-001 Ophthalmic Solution 0.1%
Description: CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
Study: NCT05141682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Description: Given PO
Study: NCT06653647

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Guided Imagery Therapy
Description: Participants will be asked to listen to a pre-recorded, 10 to 15 minute guided imagery therapy (GIT) session via mobile application 5 out of 7 days per week for 8 weeks in addition to their usual care for their abdominal pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided Imagery Therapy
Description: Participants will be asked to listen to a pre-recorded, 10 to 15 minute guided imagery therapy (GIT) session via mobile application 5 out of 7 days per week for 8 weeks in addition to their usual care for their abdominal pain.
Study: NCT04760275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: This will be a single-blind SMART design of 24 weeks duration that will employ two sequential levels of randomization, one in each of two 12-week stages of the study.~In Stage 1, participants will be randomized 1:1 to receive 12 weeks of the medication fluoxetine in upward-titrated dosages. In Stage 2, also 12 weeks in duration, participants who remit during the first 12 weeks of treatment will continue maintenance-level therapy with fluoxetine. All participants who do not remit will be randomized (1:1) to either (1) optimization of fluoxetine (increasing the dose of fluoxetine as tolerated), or (2) optimization of fluoxetine and addition of Cognitive Behavioral Therapy (CBT).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: This will be a single-blind SMART design of 24 weeks duration that will employ two sequential levels of randomization, one in each of two 12-week stages of the study.~In Stage 1, participants will be randomized 1:1 to receive 12 weeks of weekly CBT implemented with Coping Cat (CC). In Stage 2, also 12 weeks in duration, participants who remit during the first 12 weeks of treatment will continue maintenance-level therapy with CBT. All participants who do not remit will be randomized (1:1) to either (1) optimization of CBT (intensifying exposure practice and skills review), or (2) optimization of CBT and addition of the medication fluoxetine.
Study: NCT06602596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hoosier Sport
Description: The Hoosier Sport intervention is an 8-week program designed for students in PE classes, focusing on enhancing physical activity and promoting health through sport. The curriculum includes unique sports activities, leadership exercises, and health education, aimed at improving students' physical and psychological well-being. The program also addresses the effects of screen time and social media on physical activity, encouraging healthier behaviors. Throughout the intervention, students wear AX3 accelerometers to track changes in their physical activity levels, helping to assess the program's impact.
Study: NCT06652035

Intervention type: DIETARY_SUPPLEMENT
Intervention: Quevir® (Quercetin Phytosome®)
Description: 500 mg Quevir® (Quercetin Phytosome®) tablet

Intervention type: DIETARY_SUPPLEMENT
Intervention: Bactoblis®
Description: Probiotic Streptococcus Salivarius K12 (ATCC BAA-1024)
Study: NCT06662708

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Accurate Prediction Artificial Intelligence Models
Description: Diagnostic Test: Accurate Prediction Artificial Intelligence Models Post-operative pathology, precise pre-operative diagnosis (including benign and malignant, invasive, grading, subtypes) or 3D lesion modelling will be predicted based on the AI predictive model in response to the information provided
Study: NCT06664060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osteoimplant
Description: 30 lower third molars will be selected and prescribed preoperative treatment with two units of Osteoimplant Complex® 5 days prior to surgery and postoperative treatment with one unit of Osteoimplant® for 8 weeks from the time of surgery. Both nutritional supplements will be administered every 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 lower wisdom teeth will be selected and prescribed placebo, both preoperatively 5 days prior to surgery and postoperatively for 8 weeks from the time of surgery.
Study: NCT06661980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injectable Solution
Description: Dexmedetomidine 200 mcg/ 2 mL IV.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline IV.
Study: NCT06664632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exp
Description: Participants in this group will receive treatment using the Knee Sync Partner, a novel portable device designed to provide electrical traction and stimulation specifically for the knee joint.~controlled mechanical traction to the knee joint to reduce joint contact pressure, enhance synovial fluid flow, and increase joint space. This is expected to alleviate pain and improve mobility.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: This will include a combination of isometric and isotonic exercises aimed at strengthening the knee musculature, enhancing joint stability, and reducing pain. The exercise regimen will focus on major muscle groups supporting the knee, such as the quadriceps, hamstrings, and calf muscles.
Study: NCT06663228

Intervention type: DIAGNOSTIC_TEST
Intervention: MMS
Description: miniature mass spectrometry with AI assistance